SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Henriksson Niklas)
 

Sökning: WFRF:(Henriksson Niklas) > High risk of in-bre...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005959naa a2200445 4500
001oai:lup.lub.lu.se:ddb1af8c-99d0-4bf4-b185-ef92945b2b79
003SwePub
008160401s2014 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/46923762 URI
0247 a https://doi.org/10.1007/s10549-014-3115-32 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Nilsson, Martinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund,Division of Clinical Genetics,Department of Laboratory Medicine4 aut0 (Swepub:lu)med-mnn
2451 0a High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
264 c 2014-09-04
264 1b Springer Science and Business Media LLC,c 2014
300 a 8 s.
338 a electronic2 rdacarrier
520 a The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n = 118). Endpoints were local recurrence as first recurrence (LR), overall survival (OS), breast cancer death, and distant recurrence. Cumulative incidence was calculated in the presence of competing risks. For calculation of hazard ratios and for multivariable analysis, cause-specific Cox proportional hazards regression was used. Compared to M, BCT was associated with an increased risk of LR in univariable analysis (HR 4.0; 95 % CI 1.6-9.8) and in multivariable analysis adjusting for tumor stage, age, and use of adjuvant chemotherapy (HR 2.9; CI 1.1-7.8). Following M, all local recurrences were seen in the first 5 years after breast cancer diagnosis. Following BCT, the rate of LR continued to be high also after the first 5 years. The cumulative incidence of LR in the BCT group was 15, 25, and 32 % after 5, 10, and 15 years, respectively. There were no significant differences between BCT and M for OS, breast cancer death, or distant recurrence. BRCA1/2 mutation carriers treated with BCT have a high risk of LR, many of which are new primary breast cancers. This must be thoroughly discussed with the patient and is an example of how rapid treatment-focused genetic testing could influence choice of treatment.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Werner Hartman, Lindau Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)li3247we
7001 a Kristoffersson, Ulfu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)kgen-ukr
7001 a Johannsson, Oskar Thoru National University Hospital of Iceland4 aut0 (Swepub:lu)extLU-1462
7001 a Borg, Åkeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-abo
7001 a Henriksson, Karin4 aut
7001 a Lanke, Elsau Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)medf-ela
7001 a Olsson, Håkanu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Institutionen för kliniska vetenskaper, Lund,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Department of Clinical Sciences, Lund,Breastcancer-genetics,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-hol
7001 a Loman, Niklasu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-nlo
7102 a Tumörmikromiljöb Sektion I4 org
7730 t Breast Cancer Research and Treatmentd : Springer Science and Business Media LLCg 147:3, s. 571-578q 147:3<571-578x 1573-7217x 0167-6806
8564 u https://portal.research.lu.se/files/1483199/5276941x primaryx freey FULLTEXT
8564 u http://www.ncbi.nlm.nih.gov/pubmed/25187270?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1007/s10549-014-3115-3x freey FULLTEXT
8564 u https://link.springer.com/content/pdf/10.1007%2Fs10549-014-3115-3.pdf
8564 8u https://lup.lub.lu.se/record/4692376
8564 8u https://doi.org/10.1007/s10549-014-3115-3

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy